FAPI成像：突破传统PET/CT在癌症诊断中的局限性

董欣; 孙瑶; 汪菲; 张术; 谢国柱

doi:10.12122/j.issn.1674-4500.2024.05.16

FAPI成像：突破传统PET/CT在癌症诊断中的局限性

doi: 10.12122/j.issn.1674-4500.2024.05.16

南方医科大学南方医院放疗科，广东广州 510515

基金项目: 国家自然科学基金（82373302）；广州市科技计划“领航”项目（2024A04J6613）

详细信息

作者简介:
董欣，在读博士研究生，E-mail: daisydx98@qq.com

通讯作者:
谢国柱，博士，教授，博士生导师，E-mail: xieguozhu@126.com

计量
- 文章访问数: 189
- HTML全文浏览量: 117
- PDF下载量: 29
- 被引次数: 0
出版历程
- 收稿日期: 2024-03-02
- 刊出日期: 2024-05-20

FAPI imaging: breaking the limitations of traditional PET/CT in cancer diagnosis

Department of Radiation Therapy, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China

Funds: Supported by National Natural Science Foundation of China (82373302)

摘要

摘要: 近年来，传统的¹⁸F-氟代脱氧葡萄糖PET/CT在癌症诊断中得到广泛应用，但其在检测微小转移和淋巴结转移及显像特异性方面存在一定局限性。成纤维细胞激活蛋白α（FAPα）是肿瘤微环境中肿瘤相关成纤维细胞的特征性分子标记之一，其在90%的恶性实体瘤中呈现出高表达模式。靶向FAPα的新型放射性显像剂-⁶⁸Ga标记的成纤维细胞激活蛋白抑制剂（⁶⁸Ga-FAPI），已在多种肿瘤中显示出突破性的诊断潜力。本文综述了FAPI成像技术的分子基础及发展历程，并回顾了FAPI成像在乳腺癌、肺癌和胰腺癌等多种癌症中的临床应用现状，展示了其在诊断效能上相对于传统¹⁸F-FDG的优势，最后讨论了FAPI显像在当前临床推广时面临的主要挑战，旨在突显FAPI成像在癌症诊断中的巨大潜力及其未来的研究方向，以推动该技术的进一步完善和在临床实践中的广泛应用。
- FAPI /
- PET-CT /
- 放射性显像剂 /
- 癌症诊断
Abstract: In recent years, traditional ¹⁸F-FDG PET/CT has been widely used in cancer diagnosis. However, it has certain limitations in detecting small metastases and lymph node metastases, as well as imaging specificity. Fibroblast activation protein-α (FAPα) is overexpressed on cancer-associated fibroblasts in approximately 90% of malignant solid tumors. ⁶⁸Ga-labelled radiopharmaceuticals-FAP-inhibitors (FAPI)-have been developed for PET by targeting FAPα, and showed breakthrough diagnostic potential in various tumors. This article reviews the molecular basis and development history of FAPI imaging technology, and reviews the current clinical application status of FAPI imaging in various cancers such as breast cancer, lung cancer, and pancreatic cancer, showing its diagnostic efficacy compared to traditional ¹⁸F-FDG. Finally, it discusses the main challenges FAPI imaging faces in current clinical promotion, aiming to highlight the great potential of FAPI imaging in cancer diagnosis and its future research directions, to promote further improvement of the technology and its widespread application in clinical practice.
- FAPI /
- PET-CT /
- radiopharmaceuticals /
- cancer diagnosis

HTML全文

图 1 FAPα小分子抑制剂的代际发展

Figure 1. Intergenerational development of FAPI.

下载: 全尺寸图片幻灯片

参考文献(56)

[1]	Ell PJ. The contribution of PET/CT to improved patient management[J]. Br J Radiol, 2006, 79(937): 32-6. doi: 10.1259/bjr/18454286
[2]	Lind P, Igerc I, Beyer T, et al. Advantages and limitations of FDG PET in the follow-up of breast cancer[J]. Eur J Nucl Med Mol Imaging, 2004, 31(Suppl 1): S125-34.
[3]	Hess S, Scholtens AM, Gormsen LC. Patient preparation and patient-related challenges with FDG-PET/CT in infectious and inflammatory disease[J]. PET Clin, 2020, 15(2): 125-34. doi: 10.1016/j.cpet.2019.11.001
[4]	Yang LJ, Ma L, Lai DM. Over-expression of fibroblast activation protein alpha increases tumor growth in xenografts of ovarian cancer cells[J]. Acta Biochim Biophys Sin, 2013, 45(11): 928-37. doi: 10.1093/abbs/gmt095
[5]	Das S, Valton J, Duchateau P, et al. Stromal depletion by TALEN-edited universal hypoimmunogenic FAP-CAR T cells enables infiltration and anti-tumor cytotoxicity of tumor antigen-targeted CAR-T immunotherapy[J]. Front Immunol, 2023, 14: 1172681. doi: 10.3389/fimmu.2023.1172681
[6]	Liu JY, Huang CQ, Peng CW, et al. Stromal fibroblast activation protein alpha promotes gastric cancer progression via epithelial-mesenchymal transition through Wnt/β-catenin pathway[J]. BMC Cancer, 2018, 18(1): 1099. doi: 10.1186/s12885-018-5035-9
[7]	Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts[J]. J Biol Chem, 1999, 274(51): 36505-12. doi: 10.1074/jbc.274.51.36505
[8]	Klemann C, Wagner L, Stephan M, et al. Cut to the chase: a review of CD26/dipeptidyl peptidase-4's (DPP4) entanglement in the immune system[J]. Clin Exp Immunol, 2016, 185(1): 1-21. doi: 10.1111/cei.12781
[9]	Larrinaga G, Perez I, Blanco L, et al. Increased prolyl endopeptidase activity in human neoplasia[J]. Regul Pept, 2010, 163(1/2/3): 102-6.
[10]	Hu Y, Ma LF, Wu M, et al. Synthesis and structure-activity relationship of N-alkyl Gly-boro-Pro inhibitors of DPP4, FAP, and DPP7[J]. Bioorg Med Chem Lett, 2005, 15(19): 4239-42. doi: 10.1016/j.bmcl.2005.06.075
[11]	Edosada CY, Quan C, Wiesmann C, et al. Selective inhibition of fibroblast activation protein protease based on dipeptide substrate specificity[J]. J Biol Chem, 2006, 281(11): 7437-44. doi: 10.1074/jbc.M511112200
[12]	Tran T, Quan C, Edosada CY, et al. Synthesis and structure-activity relationship of N-acyl-Gly-, N-acyl-Sar-and N-blocked-boroPro inhibitors of FAP, DPP4, and POP[J]. Bioorg Med Chem Lett, 2007, 17(5): 1438-42. doi: 10.1016/j.bmcl.2006.11.072
[13]	Poplawski SE, Lai JH, Li YH, et al. Identification of selective and potent inhibitors of fibroblast activation protein and prolyl oligopeptidase[J]. J Med Chem, 2013, 56(9): 3467-77. doi: 10.1021/jm400351a
[14]	Tsai TY, Hsu T, Chen CT, et al. Rational design and synthesis of potent and long-lasting glutamic acid-based dipeptidyl peptidase Ⅳ inhibitors[J]. Bioorg Med Chem Lett, 2009, 19(7): 1908-12. doi: 10.1016/j.bmcl.2009.02.061
[15]	Tsai TY, Yeh TK, Chen X, et al. Substituted 4-carboxymethylpyro-glutamic acid diamides as potent and selective inhibitors of fibroblast activation protein[J]. J Med Chem, 2010, 53(18): 6572-83. doi: 10.1021/jm1002556
[16]	Ryabtsova O, Jansen K, van Goethem S, et al. Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP/prolyl oligopeptidase (PREP)-selectivity[J]. Bioorg Med Chem Lett, 2012, 22(10): 3412-7. doi: 10.1016/j.bmcl.2012.03.107
[17]	Jansen K, Heirbaut L, Cheng JD, et al. Selective inhibitors of fibroblast activation protein (FAP) with a (4-quinolinoyl)-glycyl-2-cyanopyrrolidine scaffold[J]. ACS Med Chem Lett, 2013, 4(5): 491-6. doi: 10.1021/ml300410d
[18]	Jansen K, Heirbaut L, Verkerk R, et al. Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl) glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP)[J]. J Med Chem, 2014, 57(7): 3053-74. doi: 10.1021/jm500031w
[19]	Loktev A, Lindner T, Mier W, et al. A tumor-imaging method targeting cancer-associated fibroblasts[J]. J Nucl Med, 2018, 59 (9): 1423-9. doi: 10.2967/jnumed.118.210435
[20]	Lindner T, Loktev A, Altmann A, et al. Development of quinoline-based theranostic ligands for the targeting of fibroblast activation protein[J]. Nucl Med, 2018, 59(9): 1415-22. doi: 10.2967/jnumed.118.210443
[21]	Loktev A, Lindner T, Burger EM, et al. Development of fibroblast activation protein-targeted radiotracers with improved tumor retention[J]. J Nucl Med, 2019, 60(10): 1421-9. doi: 10.2967/jnumed.118.224469
[22]	Jiang X, Wang XX, Shen TP, et al. FAPI-04 PET/CT using ¹⁸AlF labeling strategy: automatic synthesis, quality control, and in vivo assessment in patient[J]. Front Oncol, 2021, 11: 649148. doi: 10.3389/fonc.2021.649148
[23]	Wei YC, Zheng JS, Ma L, et al. ¹⁸F-NOTA-FAPI-04: FAP-targeting specificity, biodistribution, and PET/CT imaging of various cancers[J]. Eur J Nucl Med Mol Imaging, 2022, 49(8): 2761-73. doi: 10.1007/s00259-022-05758-0
[24]	Elboga U, Sahin E, Kus T, et al. Superiority of ⁶⁸Ga-fapi pet/ct scan in detecting additional lesions compared to ¹⁸FDG pet/ct scan in breast cancer[J]. Ann Nucl Med, 2021, 35(12): 1321-31. doi: 10.1007/s12149-021-01672-x
[25]	Pang YZ, Zhao L, Chen HJ. ⁶⁸Ga-FAPI outperforms ¹⁸F-FDG PET/CT in identifying bone metastasis and peritoneal carcinomatosis in a patient with metastatic breast cancer[J]. Clin Nucl Med, 2020, 45 (11): 913-5. doi: 10.1097/RLU.0000000000003263
[26]	Li TY, Jiang XJ, Zhang ZQ, et al. Case Report: ⁶⁸Ga-FAPI PET/CT, a more advantageous detection mean of gastric, peritoneal, and ovarian metastases from breast cancer[J]. Front Oncol, 2022, 12: 1013066. doi: 10.3389/fonc.2022.1013066
[27]	Kömek H, Can CN, Güzel Y, et al. ⁶⁸Ga-FAPI-04 PET/CT, a new step in breast cancer imaging: a comparative pilot study with the ¹⁸F-FDG PET/CT[J]. Ann Nucl Med, 2021, 35(6): 744-52. doi: 10.1007/s12149-021-01616-5
[28]	Sahin E, Kus T, Aytekin A, et al. ⁶⁸Ga-FAPI PET/CT as an alternative to ¹⁸F-FDG PET/CT in the imaging of invasive lobular breast carcinoma[J]. J Nucl Med, 2024, 65(4): 512-9. doi: 10.2967/jnumed.123.266798
[29]	Chen L, Zheng S, Chen LY, et al. ⁶⁸Ga-labeled fibroblast activation protein inhibitor PET/CT for the early and late prediction of pathologic response to neoadjuvant chemotherapy in breast cancer patients: a prospective study[J]. J Nucl Med, 2023, 64(12): 1899-905. doi: 10.2967/jnumed.123.266079
[30]	Ding F, Huang C, Liang CY, et al. ⁶⁸Ga-FAPI-04 vs ¹⁸F-FDG in a longitudinal preclinical PET imaging of metastatic breast cancer[J]. Eur J Nucl Med Mol Imaging, 2021, 49(1): 290-300. doi: 10.1007/s00259-021-05442-9
[31]	Kessler L, Ferdinandus J, Hirmas N, et al. Pitfalls and common findings in ⁶⁸Ga-FAPI PET: a pictorial analysis[J]. J Nucl Med, 2022, 63(6): 890-6. doi: 10.2967/jnumed.121.262808
[32]	Telo S, Calderoni L, Vichi S, et al. Alternative and new radiopharmaceutical agents for lung cancer[J]. Curr Radiopharm, 2020, 13(3): 185-94. doi: 10.2174/1874471013666191223151402
[33]	Wang LJ, Tang GH, Hu KZ, et al. Comparison of ⁶⁸Ga-FAPI and ¹⁸F-FDG PET/CT in the evaluation of advanced lung cancer[J]. Radiology, 2022, 303(1): 191-9. doi: 10.1148/radiol.211424
[34]	Giesel FL, Heussel CP, Lindner T, et al. FAPI-PET/CT improves staging in a lung cancer patient with cerebral metastasis[J]. Eur J Nucl Med Mol Imaging, 2019, 46(8): 1754-5. doi: 10.1007/s00259-019-04346-z
[35]	Röhrich M, Daum J, Gutjahr E, et al. Diagnostic potential of supplemental static and dynamic ⁶⁸Ga-FAPI-46 PET for primary ¹⁸F-FDG-negative pulmonary lesions[J]. J Nucl Med, 2024. 10.2967/jnumed. 123.267103. doi: 10.2967/jnumed.123.267103
[36]	Shang QH, Zhao L, Pang YZ, et al. Differentiation of reactive lymph nodes and tumor metastatic lymph nodes with ⁶⁸Ga-FAPI PET/CT in a patient with squamous cell lung cancer[J]. Clin Nucl Med, 2022, 47(5): 458-61. doi: 10.1097/RLU.0000000000003998
[37]	Spektor AM, Gutjahr E, Lang M, et al. Immunohistochemical FAP expression reflects ⁶⁸Ga-FAPI PET imaging properties of low- and high-grade intraductal papillary mucinous neoplasms and pancreatic ductal adenocarcinoma[J]. J Nucl Med, 2024, 65(1): 52-8. doi: 10.2967/jnumed.123.266393
[38]	Kessler L, Hirmas N, Pabst KM, et al. 68Ga-labeled fibroblast activation protein inhibitor (⁶⁸Ga-FAPI) PET for pancreatic adenocarcinoma: data from the ⁶⁸Ga-FAPI PET observational trial[J]. J Nucl Med, 2023, 64(12): 1910-7. doi: 10.2967/jnumed.122.264827
[39]	Liu QF, Shi S, Liu S, et al. The added value of ⁶⁸Ga-DOTA-FAPI-04 PET/CT in pancreatic cancer: a comparison to ¹⁸F-FDG[J]. Eur Radiol, 2023, 33(7): 5007-16. doi: 10.1007/s00330-023-09445-y
[40]	Ding J, Qiu JD, Hao ZX, et al. Comparing the clinical value of baseline ⁶⁸Ga-FAPI-04 PET/CT and ¹⁸F-FDG PET/CT in pancreatic ductal adenocarcinoma: additional prognostic value of the distal pancreatitis[J]. Eur J Nucl Med Mol Imaging, 2023, 50(13): 4036-50. doi: 10.1007/s00259-023-06297-y
[41]	Xu WZ, Cai JY, Peng TX, et al. Fibroblast activation protein-targeted PET/CT with 18F-fibroblast activation protein inhibitor-74 for evaluation of gastrointestinal cancer: comparison with 18F-FDG PET/CT[J]. J Nucl Med, 2024, 65(1): 40-51. doi: 10.2967/jnumed.123.266329
[42]	Ding J, Qiu JD, Hao ZX, et al. Prognostic value of preoperative ⁶⁸Ga-FAPI-04 PET/CT in patients with resectable pancreatic ductal adenocarcinoma in correlation with immunohistological characteristics[J]. Eur J Nucl Med Mol Imaging, 2023, 50(6): 1780-91. doi: 10.1007/s00259-022-06100-4
[43]	Pang YZ, Zhao L, Shang QH, et al. Positron emission tomography and computed tomography with ⁶⁸Ga-fibroblast activation protein inhibitors improves tumor detection and staging in patients with pancreatic cancer[J]. Eur J Nucl Med Mol Imaging, 2022, 49(4): 1322-37. doi: 10.1007/s00259-021-05576-w
[44]	Kessler L, Ferdinandus J, Hirmas N, et al. ⁶⁸Ga-FAPI as a diagnostic tool in sarcoma: data from the ⁶⁸Ga-FAPI PET prospective observational trial[J]. J Nucl Med, 2022, 63(1): 89-95. doi: 10.2967/jnumed.121.262096
[45]	Lanzafame H, Mavroeidi IA, Pabst KM, et al. ⁶⁸Ga-fibroblast activation protein inhibitor PET/CT improves detection of intermediate and low-grade sarcomas and identifies candidates for radiopharmaceutical therapy[J]. J Nucl Med, 2024. doi: 10.2967/jnumed.123.267248.
[46]	Röhrich M, Loktev A, Wefers AK, et al. IDH-wildtype glioblastomas and grade Ⅲ/Ⅳ IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein-specific PET/CT[J]. Eur J Nucl Med Mol Imaging, 2019, 46(12): 2569-80. doi: 10.1007/s00259-019-04444-y
[47]	Yao YT, Tan XF, Yin WY, et al. Performance of ¹⁸F-FAPI PET/CT in assessing glioblastoma before radiotherapy: a pilot study[J]. BMC Med Imaging, 2022, 22(1): 226. doi: 10.1186/s12880-022-00952-w
[48]	Rajaraman V, Meenakshi LA, Selvaraj AJ, et al. Role of ⁶⁸Ga-FAPI PET/CT in assessing hepatobiliary malignancies: a prospective pilot study[J]. Clin Nucl Med, 2023, 48(6): e281-e288. doi: 10.1097/RLU.0000000000004641
[49]	Zhang J, He Q, Jiang SQ, et al. ¹⁸FAPI PET/CT in the evaluation of focal liver lesions with ¹⁸FDG non-avidity[J]. Eur J Nucl Med Mol Imaging, 2023, 50(3): 937-50. doi: 10.1007/s00259-022-06022-1
[50]	Siripongsatian D, Promteangtrong C, Kunawudhi A, et al. Comparisons of quantitative parameters of ⁶⁸Ga-labelled fibroblast activating protein inhibitor (FAPI) PET/CT and ¹⁸F-FDG PET/CT in patients with liver malignancies[J]. Mol Imaging Biol, 2022, 24 (5): 818-29. doi: 10.1007/s11307-022-01732-2
[51]	Lan LJ, Zhang SM, Xu TT, et al. Prospective comparison of ⁶⁸Ga-FAPI versus ¹⁸F-FDG PET/CT for tumor staging in biliary tract cancers[J]. Radiology, 2022, 304(3): 648-57. doi: 10.1148/radiol.213118
[52]	Gündoğan C, Kömek H, Can CN, et al. Comparison of 18F-FDG PET/CT and ⁶⁸Ga-FAPI-04 PET/CT in the staging and restaging of gastric adenocarcinoma[J]. Nucl Med Commun, 2022, 43(1): 64-72. doi: 10.1097/MNM.0000000000001489
[53]	Lin R, Lin ZF, Chen ZY, et al. ⁶⁸Ga-DOTA-FAPI-04 PET/CT in the evaluation of gastric cancer: comparison with ¹⁸FDG PET/CT[J]. Eur J Nucl Med Mol Imag, 2022, 49(8): 2960-71. doi: 10.1007/s00259-022-05799-5
[54]	Zhang SM, Wang W, Xu TT, et al. Comparison of diagnostic efficacy of ⁶⁸Ga-FAPI-04 and ¹⁸FDG PET/CT for staging and restaging of gastric cancer[J]. Front Oncol, 2022, 12: 925100. doi: 10.3389/fonc.2022.925100
[55]	Zheng S, Lin R, Chen SM, et al. Characterization of the benign lesions with increased ⁶⁸Ga-FAPI-04 uptake in PET/CT[J]. Ann Nucl Med, 2021, 35(12): 1312-20. doi: 10.1007/s12149-021-01673-w
[56]	Qin CX, Song Y, Liu X, et al. Increased uptake of ⁶⁸Ga-DOTA-FAPI-04 in bones and joints: metastases and beyond[J]. Eur J Nucl Med Mol Imaging, 2022, 49(2): 709-20. doi: 10.1007/s00259-021-05472-3